Robin Brenner

867 total citations
12 papers, 366 citations indexed

About

Robin Brenner is a scholar working on Oncology, Cancer Research and Biotechnology. According to data from OpenAlex, Robin Brenner has authored 12 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 4 papers in Cancer Research and 3 papers in Biotechnology. Recurrent topics in Robin Brenner's work include Pancreatic and Hepatic Oncology Research (7 papers), Cancer Genomics and Diagnostics (4 papers) and Cancer Research and Treatments (3 papers). Robin Brenner is often cited by papers focused on Pancreatic and Hepatic Oncology Research (7 papers), Cancer Genomics and Diagnostics (4 papers) and Cancer Research and Treatments (3 papers). Robin Brenner collaborates with scholars based in United States, Ireland and Israel. Robin Brenner's co-authors include David P. Kelsen, Kenneth H. Yu, Marinela Capanu, Eileen M. O’Reilly, Maeve A. Lowery, Joanne F. Chou, Richard Kinh Gian, Alice P. Chen, Jonathan W. Lee and Talia Golan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Robin Brenner

11 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin Brenner United States 5 286 205 104 70 49 12 366
Elisabeth Breit Germany 7 210 0.7× 174 0.8× 86 0.8× 64 0.9× 25 0.5× 8 315
María Teresa Sanz Casla Spain 10 301 1.1× 154 0.8× 119 1.1× 107 1.5× 16 0.3× 23 425
Hiroyuki Konno Japan 9 199 0.7× 83 0.4× 138 1.3× 60 0.9× 15 0.3× 9 333
Derek M. Kohler Canada 8 134 0.5× 106 0.5× 139 1.3× 135 1.9× 12 0.2× 10 293
Yuuji Nakahara Japan 12 278 1.0× 94 0.5× 355 3.4× 61 0.9× 23 0.5× 14 534
Anthony Kawesha United Kingdom 4 223 0.8× 112 0.5× 99 1.0× 35 0.5× 11 0.2× 5 276
Rosa Saltarelli Italy 5 304 1.1× 185 0.9× 78 0.8× 110 1.6× 10 0.2× 9 356
Kazuaki Yokomizo Japan 12 148 0.5× 112 0.5× 264 2.5× 69 1.0× 28 0.6× 27 431
Shineng Zhang China 12 204 0.7× 276 1.3× 365 3.5× 55 0.8× 18 0.4× 29 520
Lydia Gutiérrez-González Spain 7 161 0.6× 122 0.6× 189 1.8× 112 1.6× 60 1.2× 8 441

Countries citing papers authored by Robin Brenner

Since Specialization
Citations

This map shows the geographic impact of Robin Brenner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Brenner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Brenner more than expected).

Fields of papers citing papers by Robin Brenner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Brenner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Brenner. The network helps show where Robin Brenner may publish in the future.

Co-authorship network of co-authors of Robin Brenner

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Brenner. A scholar is included among the top collaborators of Robin Brenner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Brenner. Robin Brenner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Tuli, Richard, Fergus Keane, Joshua D. Schoenfeld, et al.. (2023). A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.. Journal of Clinical Oncology. 41(16_suppl). 4164–4164. 1 indexed citations
2.
Keane, Fergus, Joshua D. Schoenfeld, Catherine O’Connor, et al.. (2023). A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC).. Journal of Clinical Oncology. 41(4_suppl). 725–725. 1 indexed citations
3.
4.
O’Reilly, Eileen M., Jonathan W. Lee, Mark M. Zalupski, et al.. (2020). Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. Journal of Clinical Oncology. 38(13). 1378–1388. 253 indexed citations
5.
O’Reilly, Eileen M., Jonathan W. Lee, Mark M. Zalupski, et al.. (2020). A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.. Journal of Clinical Oncology. 38(4_suppl). 639–639. 8 indexed citations
6.
Yu, Kenneth H., Simon Mantha, Robin Brenner, et al.. (2018). Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.. Journal of Clinical Oncology. 36(4_suppl). 405–405. 3 indexed citations
7.
Yu, Kenneth H., Simon Mantha, Robin Brenner, et al.. (2018). A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis. Annals of Oncology. 29. viii248–viii248. 1 indexed citations
8.
Lowery, Maeve A., James J. Harding, Kenneth H. Yu, et al.. (2017). Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC).. Journal of Clinical Oncology. 35(4_suppl). 295–295. 2 indexed citations
9.
Lowery, Maeve A., Kenneth H. Yu, David P. Kelsen, et al.. (2017). A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Cancer. 123(23). 4556–4565. 63 indexed citations
10.
Furman, Richard R., Andres Sirulnik, Robin Brenner, et al.. (2002). A Phase II Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Low-Grade Lymphomas. Blood. 100(11). 4758. 1 indexed citations
11.
Swenson, O & Robin Brenner. (1968). Aggressive Approach to the Treatment of Wilms' Tumor. CA A Cancer Journal for Clinicians. 18(4). 241–243. 1 indexed citations
12.
Swenson, O & Robin Brenner. (1967). Aggressive Approach To The Treatment Of Wilmsʼ Tumor. Annals of Surgery. 166(4). 657–669. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabeth Breit Breakdown of academic impact, for papers by María Teresa Sanz Casla Breakdown of academic impact, for papers by Hiroyuki Konno Breakdown of academic impact, for papers by Derek M. Kohler Breakdown of academic impact, for papers by Yuuji Nakahara Breakdown of academic impact, for papers by Anthony Kawesha Breakdown of academic impact, for papers by Rosa Saltarelli Breakdown of academic impact, for papers by Kazuaki Yokomizo Breakdown of academic impact, for papers by Shineng Zhang Breakdown of academic impact, for papers by Lydia Gutiérrez-González
Rankless by CCL
2026